Introduction
Adenovirus (Ad) is one of the most efficient vectors for gene delivery in a wide range of tissues. However, following Ad infection, a strong immune response develops that limits the duration of transgene expression and precludes adenoviral readministration. Within a few days following Ad administration, polynuclear cells and macrophages infiltrate Ad-infected tissues. Subsequently, transduced cells are specifically killed by cytotoxic T lymphocytes (CTL), which recognize viral-or transgene-derived peptides. In addition, antibodies directed against the viral capsid are also synthesized. Some of these can neutralize the virus, rendering any subsequent administration inefficient. 1, 2 Several strategies have been designed to counter the host's immune response against Ad. In one approach, the adenoviral genome was modified to render the adenoviral vector less immunogenic. Cells transduced by adenoviral vectors deleted for early regions E1 and E4, or E2, or helper-dependent Ad devoid of viral genes, survive longer. Persistence of transgene expression stems from reduced Ad late gene expression. 1, 3 Although such a strategy based on the deletion of the majority of viral genes reduces host-specific immune response, intrinsic viral capsid immunogenicity remains unsolved. Indeed, Ad particles or capsids trigger the innate immune response, 4, 5 and chemokines are synthesized following capsid-dependent activation of nuclear factorkappa B (NF-kB). [6] [7] [8] [9] Moreover, even in absence of de novo viral protein synthesis, adenoviral vectors still induce a cytotoxic response 4, 10 and, at least in humans, anti-Ad CTL targets capsid components. 11 Understanding the host immune response against recombinant Ad is crucial to the development of successful clinical trials employing adenoviral vectors. The overall immunogenicity of Ad, particularly capsid components, emphasizes the need to control key steps of immune activation. To this end, several works have examined the contribution of proinflammatory cytokines interleukin (IL-)1, IL-6 and tumor necrosis factor (TNF)-a to the anti-Ad immune response. Thus, in a model of gene transfer to the lung, recombinant Ad expressing a potent inhibitor of IL-1 failed to prevent Ad-induced inflammation. 12 However, following intravenous (i.v.) injection of recombinant Ad in mice deficient in IL-1 type 1 receptor or in wild-type mice treated with antibodies to IL-1, a reduction of innate and inflammatory host responses was reported. 13 In pioneering clinical trials, Crystal's group described an inflammatory process in the lung of cystic fibrosis patients following Ad gene delivery, and they suggested that IL-6 is a prominent actor in the anti-Ad immune response. 14 However, in a previous study, we did not observe any significant improvement in transgene expression in mice deficient for IL-6 (IL-6
À/À
). Moreover, we observed in this model an increase in serum IL-1b and TNF-a levels, suggesting the existence of compensatory mechanisms between cytokines. 15 The role of TNF-a in the immune response against Ad was suspected when this cytokine was detected at a very early stage following virus administration by different routes of injection. 5, 8, [15] [16] [17] [18] This was confirmed by the discovery of a set of genes (early region E3B) in the wild-type Ad encoding proteins able to counteract TNF-a functions. These proteins act independently to stop TNF-a-induced cytolysis and inflammation by interfering with transduction pathway elicited by the binding of TNF-a to type 1 TNF receptor (TNFR1). Specifically, the heterodimer E3-10.4 kDa/E3-14.5 kDa and the E3-14.7 kDa protein inhibit TNF-a-dependent translocation of phospholipase A2 from the cytosol to the membrane, thus preventing the release of inflammatory mediators. Moreover, the E3-14.7 kDa protein interferes with TNF-a-induced apoptosis by blocking the activation of caspase 8, a protein common to both Fas and TNFR1 transduction pathways (for reviews see Horwitz 19 and Lichtenstein et al.
20
). Finally, adenoviral E3-10.4 kDa/E3-14.5 kDa proteins were shown to downregulate levels of TNFR1 at the plasma membrane. 21 The use of a mouse model genetically deficient in both TNF-a and lymphotoxin a (TNF-a/LTa À/À ) has allowed us to decipher the role of these two cytokineswhich both trigger the same receptors (TNFR1 and TNFR2) -in the anti-Ad immune response. In liver gene transfer experiments, TNF-a/LTa À/À mice, as compared with controls, presented a weaker inflammatory reaction and a reduced intrahepatic cellular infiltrate. The proliferative cellular responses directed against either the adenoviral antigen or the transgene product were abrogated. Interestingly, the antibody response to both the virus and the gene product was severely reduced for all isotypes. This reduction was less pronounced in heterozygous TNF-a/LTa +/À mice, underlying the notion that the strength of the humoral response is linked to the level of TNF-a/LTa. Owing to the absence of neutralizing antibodies in TNF-a/LTa À/À mice, we were able to demonstrate an efficient second administration of a recombinant Ad. 22 Crystal's group has also reported in TNF-a-deficient mice a defective antibody response to Ad together with a prolonged survival of Ad-transduced hepatocytes. 23 Taken together, these data suggested a major role for TNF-a in the establishment of the anti-Ad immune response.
In the present work, we analyzed the respective roles of TNF-a and IL-6 in mediating the host anti-Ad immune response in two ways. Firstly, we administrated a competitive inhibitor of cellular TNFR1 and 2 along with a transgene in a strategy drawing upon immunointervention with an Ad encoding a fusion protein between the Fc portion of mouse IgG1 and the extracellular domain of human TNFR1 (AdTNFR1-Ig). This soluble TNFR1-Ig molecule displays two binding sites for TNF-a and is a competitive inhibitor of cellular TNFR1 and 2. 24 In the second, to unravel any possible cooperation between TNF-a and IL-6 in mounting an efficient anti-Ad immune response, a transgene was administrated along with AdTNFR1-Ig in wild-type and IL-6 À/À . Strategies to inhibit TNF-a and IL-6 in gene therapy are discussed.
Results

Neutralization of TNF-a by soluble TNFR1-Ig leads to increased transgene expression
In order to decipher the contribution of TNF-a and IL-6 to the immune responses elicited by Ad-mediated gene transfer, we used two different tools. First, a recombinant Ad encoding a soluble TNFR1 24 was used to assess the role of TNF-a during gene transfer; second, IL-6-deficient mice 25 were used to examine how this cytokine may influence anti-Ad immune responses. As we previously reported that wild-type and IL-6-deficient mice present a comparable time course of transgene elimination, 15 the experiments were designed to assess a synergy between TNF-a and IL-6 in mounting anti-Ad immune responses. Figure 1a shows serum human a1-antitrypsin (AAT) levels in wild-type and IL-6 À/À mice injected i.v. with AdmlpAAT, which encodes soluble AAT protein along with a control Ad (AdCO1) or AdTNFR1-Ig. We observed, at different times following virus administration, markedly higher serum AAT levels in wildtype and IL-6 À/À mice injected with AdTNFR1-Ig as compared to AdCO1-injected control mice. Thus, while AdTNFR1-Ig-injected wild-type and IL-6 À/À mice present comparable serum AAT levels (mean7s.d. ¼ 572.57353.9 mg/ml and 573.27543.5 mg/ml, respectively) at day 4 post-infection (p.i.), the level is much lower in control mice (mean7s.d. ¼ 17.678.4 mg/ml, *Po0.05). In addition, high levels of serum AAT were still found at day 8 and 15 p.i. in AdTNFR1-Ig-injected wild-type and IL-6 À/À mice. Importantly, these results are not linked to a peculiar genetic background since we found also a two order of magnitude increase in AAT expression in AdTNR1-Ig-injected C57BL/6 mice from day 7 to day 14 p.i. (data not shown). Moreover, IL-6 À/À mice injected with AdTNFR1-Ig displayed a much stronger level of AAT at day 15 (58.97118.9 mg/ml), but also at day 32 p.i. (0.570.3 mg/ml) compared to both AdTNFR1-Ig or AdCO1-injected wild-type mice (Figure 1a) .
In parallel to serum AAT quantification, we monitored serum TNFR1-Ig levels by enzyme-linked immunosorbant assay (ELISA). A high serum level of this soluble receptor was detected as soon as day 1 p.i. (data not shown). As ELISA measures both free TNFR1-Ig and TNFR1-Ig/TNF-a complexes, we performed a bioassay to determine levels of free TNFR1-Ig by its ability to inhibit TNF-a-mediated cytotoxicity on WEHI 164 clone 13 cell line (Figure 1b) In another set of experiments, we substituted AdmlpAAT for Ad CMVbgal, which drives the expression of b-galactosidase (bgal) in the nucleus under the control of cytomegalovirus (CMV) promoter. Figure 2 shows immunodetection of bgal in liver sections of animals killed at different times p.i. At day 3 p.i., the same number of bgal-positive cells was observed in wild-type mice injected with AdCO1 or with AdTNFR1-Ig, and in IL-6-deficient mice injected with AdTNFR1-Ig. By day 18, only the group of mice injected with AdTNFR1-Ig displayed bgal-positive hepatocytes. To get a more accurate estimation of Ad-mediated LacZ gene transfer, we measured the bgal activity in liver lysates using a chemiluminescent assay. Table 1 shows a very high bgal activity in the three groups of mice at day 3. By day 9, AdTNFR1-Ig-treated mice displayed a significant increased bgal activity (**Po0.01) compared to AdCO1-treated mice; this was also documented by bgal immunodetection ( Figure 2 ). However, by day 18, AdTNFR1-Igtreated IL-6 À/À mice presented a tendency to express a higher level of bgal activity compared to AdTNFR1-Igor AdCO1-treated IL-6 +/+ mice, although the increase was not statistically significant. The increase in bgal activity is mainly linked to the expression of TNFR1-Ig, since both AdTNFR1-Ig injected IL-6 À/À and IL-6 +/+ mice still exhibit detectable TNFR1-Ig until day 18 p.i. (data not shown). 
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Overall, the data strongly indicates that TNF-a neutralization prolongs transgene (either bgal or AAT) expression.
Increase in transgene expression does not stem from activation of transgene promoter
The prolonged transgene expression in AdTNFR1-Iginfected wild-type and IL-6 À/À mice could stem from inhibition of TNF-a-induced promoter regulation because previous work has described inhibition of human CMV (huCMV) immediate early promoter (huCMVie) by TNF-a. 26 As, in our experiments bgal and AAT expression are driven by the huCMVie promoter and the Ad major late promoter (MLP), respectively, the increase in transgene expression observed after TNF-a neutralization may correspond to higher transcription of the transgene. To unravel this hypothesis, the level of viral DNA (particle forming unit (PFU) equivalents/mg of DNA liver) in AdCMVbgal-injected liver samples was accurately quantified by real-time polymerase chain reaction (PCR). In Table 2 , the level of viral DNA was expressed as percent of Ad DNA content in AdCO1-injected mice at day 3. From day 3 p.i., the amounts of viral DNA were similar in wild-type and IL-6 À/À mice injected with AdTNFR1-Ig as compared to AdCO1-injected mice. However, at day 9 p.i., the amount of viral DNA detected in livers of AdTNFR1-Iginjected wild-type and IL-6 À/À mice (24.35710.52% and 20.7674.62%, respectively) was significantly higher than amounts of viral DNA in livers of AdCO1-injected mice (9.1970.95%). This increase was still obvious at day 18 p.i.: 13.4672.27% and 18.5177.31% for AdTNFR1-Ig-injected wild-type and IL-6 À/À mice, respectively compared to 4.6371.04% for AdCO1-injected mice. Therefore, the higher amount of bgal protein detected in AdTNFR1-Ig-injected mice (Table 1 and Figure 2 ) results from DNA persistence and not from higher transcription of the transgene. These results indicate that inhibition of TNF-a has little or no effect on transgene promoter activation.
Neutralization of TNF-a allows a reduction of the acute response to Ad
To analyze whether TNF-a (+/À IL-6) inhibition leads to modification of hematological parameters, we collected blood samples at different times p.i. Compared to noninjected wild-type or IL-6 À/À mice, we observed in all groups of mice a severe leukopenia at day 1 and 3 p.i. (Figure 3a) as reported by others. 27 This decrease in white blood cells was linked to a strong reduction of lymphocytes counts in all groups of mice. We also noticed at day 3 p.i. a decrease in granulocytes counts in both groups of AdTNFR1-Ig-treated mice. In accordance with previous published data, 27, 28 we documented a thrombocytopenia in all groups of mice at day 1 but we also observed that mice expressing TNFR1-Ig still displayed such a reduction at day 3 p.i. (*Po0.05). We also assessed hepatotoxicity that may be induced by i.v. Ad administration by measuring serum alanine aminotransferase (ALT). There was no significant difference between all groups of mice at day 3 p.i. (data not shown). Finally, because i.v. Ad delivery has been shown to induce a strong inflammation, 15, 29 we monitored the level of serum proinflammatory cytokines at different times p.i. Figure 3b shows that IL-1b levels detected in sera 6 h p.i. were reduced in AdTNFR1-Ig-injected wildtype or IL-6 À/À mice (46.9733.4 and 19.7712.9 pg/ml, respectively, **Po0.01) compared to AdCO1-treated mice (109.7725.1 pg/ml). Moreover, levels of IL-6 in the sera of AdTNFR1-Ig-injected wild-type mice were reduced (Figure 3b , *Po0.05). Determination of serum TNF-a levels was hampered by the fact that both solublefree TNF-a and TNF-a bound to TNFR1-Ig were measured by ELISA. Thus, 6 h p.i., wild-type and IL-6-deficient mice displayed higher TNF-a levels than AdCO1-treated mice most likely because of the presence of circulating TNF-a-TNFR1-Ig complexes. However, by day 1, AdCO1-injected mice exhibited a higher TNF-a level (data not shown).
Altogether these data suggest that inhibition of TNF-a does not prevent leukopenia and thrombocytopenia observed following Ad injection and may prolong them. However, inhibition of TNF-a decreases production of proinflammatory cytokines.
TNF-a controls inflammatory cell recruitment
In order to explain the increase in transgene (AAT or bgal) expression observed in AdTNFR1-Ig-treated mice, we examined in the following experiments the host inflammatory and cellular immune response. First, to characterize the infiltrating immune cells responsible for the elimination of transgene-expressing cells, we performed immunostaining experiments. Livers from wildtype and IL-6-deficient mice injected with AdTNFR1-Ig displayed a mild reduction of CD4-and CD8-positive cells at day 9 p.i., while a strong reduction of Mac1/CD11b-positive cells was observed in AdTNFR1-Ig-treated mice compared to AdCO1-injected mice ( Figure 4) . Importantly, while we observed numerous clusters of Mac1 + cells in AdCO1-injected mice, only a TNF À/À mice, but not in wild-type injected with AdTNFR1-Ig. As AdTNFR1-Ig encodes a chimeric molecule between mouse Fc portion of IgG1 and the extracellular domain of human TNFR1, we analyzed the antibody response against the human moiety (i.e., TNFR1 extracellular domain) of the protein.
Although we detected anti-TNFR1-Ig antibodies in IL-6 wild-type mice, such antibodies were not found in IL-6-deficient mice (data not shown).
Treatment of mice with a clinically approved anti-TNF-a drug inhibited the humoral response following Ad-mediated gene transfer
In order to confirm results obtained with AdTNR1-Ig, we studied the efficacy of a clinically used anti-TNF drug (etanercept) composed of a human type 2 TNFR fused to human immunoglobulin Fc region. Mice pretreated with etanercept or PBS were injected with AdmlpAAT, then treatment with etanercept or PBS was continued bidaily for 24 days. (Figure 7c ). Altogether, these results indicate that TNF-a neutralization using etanercept recapitulated the reduced antibody responses observed above in AdTNFR1-Ig-injected wild-type and IL-6 À/À mice and underscore the importance of TNF-a and IL-6 in mounting humoral response during Ad gene transfer.
Discussion
Administration of recombinant Ad to mice stimulates innate immune responses, demonstrated by elevated serum TNF-a and IL-6 levels. 15, 18, 30 The role of TNF-a and IL-6 in regulation of Ad vector-mediated immune responses has been mainly documented in mice deficient for TNF-a or IL-6. 15,22,23 As TNF-a-deficient mice are known to be severely impaired in lymphoid organ development and inflammatory responses, we sought to decipher the role of TNF-a through Ad-mediated gene transfer of a soluble TNFR1, which is able to trap TNF-a in serum. Moreover, the experiments were performed in wild-type and IL-6-deficient mice to unravel a possible cooperation between TNF-a and IL-6 in mounting an anti-Ad immune response.
In agreement with previous reports, 31, 32 we show here that Ad-driven AAT or lacZ gene expression in the liver was significantly improved by immunointervention with soluble TNFR1. However, by quantitative PCR analysis we observed that extended transgene expression in TNFR1-Ig expressing mice is related to hepatocyte adenoviral DNA content, and not from an activation of viral promoters following TNF-a neutralization, as reported. 26, 33 This increase probably results from modulation of anti-Ad inflammatory, cellular and humoral responses. First, we monitored acute response to i.v. Ad administration. All groups of mice displayed leukopenia and thrombocytopenia after Ad injection. However, these hematological disorders were slightly prolonged in mice TNF-a and IL-6 involvement in anti-Ad immune response K Benihoud et al expressing TNFR1-Ig. Also, we described a significant reduction of proinflammatory cytokines in the sera of AdTNFR1-Ig-injected mice. This latter observation was expected since TNF-a is known to be a potent inducer of IL-6 and IL-1. 34, 35 In addition, in this study both wild-type and IL-6-deficient mice showed a significant reduction of liver cellular infiltrates as previously reported, 31, 32 suggesting that TNF-a, but not IL-6, is an essential regulator of the cellular immune response against Ad-transduced cells. Moreover, our immunohistochemical analyses revealed that CD4 + and CD8 + T lymphocytes, and Mac1 + macrophages were the cell populations reduced by TNF-a neutralization. Quantitative analysis by flow cytometry performed at day 4 p.i. confirmed this reduction in macrophage numbers, and showed that DX-5 + NK cell numbers were also significantly diminished following TNF-a inhibition. As TNF-a produced by inflammatory cells controls the expression of cell adhesion molecules on the endothelium of local blood vessels, 36 its neutralization reduces the recruitment of inflammatory cells from blood vessels, and consequently prolongs transgene expression. Neutralization of TNF-a may also impact the maturation of dendritic cells, 37 delaying the induction of the adaptive immune response to Ad. Moreover, effect of TNFR1-Ig may stem from induction of macrophages apoptosis by reverse signaling of transmembrane TNF. Such effect was observed with infliximab, a monoclonal antibody directed against TNF-a, or etanercept, a recombinant soluble TNFR2, both currently used to treat rheumatoid arthritis and Crohn's disease. [38] [39] [40] The slight effect of IL-6 on the recruitment of inflammatory cells, provides an explanation for our previous report, 15 which showed no difference between wild-type and IL-6-deficient mice in liver transgene expression and immune response after Ad-mediated gene transfer. However in the present report, while we observed that antibody responses against the Ad particle and transgene product (bgal and AAT) were only transiently reduced in wild-type mice treated with soluble TNFR1, they were markedly diminished in TNFR1-treated IL-6-deficient mice. In addition, although pharmacological studies have claimed that the TNFR1-Ig antagonist we used is non-immunogenic in mice, 24 its duration of expression was markedly shortened in wildtype mice compared to IL-6 À/À mice (day 32 vs day 102 p.i.). The earlier disappearance of TNFR1-Ig in wild-type mice is certainly linked to an antibody response to the human moiety of this antagonist (data not shown). This antibody response was not observed in mice impaired in both IL-6 and TNF-a cytokines. Importantly, lesser antibody production against virus particles and transgene products is not linked to long-term expression of TNFR1-Ig resulting in a better TNF-a neutralization, since this reduction of antibody response is obvious in wild-type mice expressing detectable levels of TNFR1-Ig. These findings demonstrate that both IL-6 and TNF-a cytokines are required for full induction of anti-Ad antibody responses, which limit the duration of transgene expression, and that impairment of IL-6 boosts the beneficial effect of TNF-a neutralization on transgene expression. This antibody reduction underlines the crucial role played by TNF-a in antigen-presenting cell maturation 37 and T-cell dependent antibody responses. 41, 42 In order to confirm the role of TNF-a in mounting humoral responses against Ad, we also treated mice with a clinically approved anti-TNF-a drug, etanercept. This protein composed of a human TNFR2 moiety fused to the human immuglobulin Fc region moiety was able to reduce anti-Ad immune response in both wild-type and IL-6-deficient mice at earlier times p.i. but only in TNF-a and IL-6 involvement in anti-Ad immune response K Benihoud et al IL-6-deficient mice at later times p.i. As observed before with TNFR1-Ig, etanercept triggered an antibody response in wild-type mice that led to its elimination. The fact that anti-Ad and anti-etanercept antibody responses were severely reduced in IL-6 À/À mice highlights the role played by both TNF-a and IL-6 in controlling antibody responses.
Our findings taken together suggest that TNF-a controls the early recruitment of inflammatory cells following delivery of Ad to the liver, while IL-6 in synergy with TNF-a controls the antibody response. These cytokines are mainly produced by Kupffer and dendritic cells following interaction between capsid components and cellular receptors. 5 A better knowledge of interactions between capsid proteins and antigen-presenting cells would be helpful in limiting their activation. Such an approach based on deletion of the RGD motif present in penton base capsid protein was reported to block phosphoinositide-3-OH kinase-dependent TNF-a production by dendritic cells. 43 This would suggest that efforts should be directed towards dampening the activation of antigenpresenting cells, and towards neutralizing the cytokines produced by immune cells. This could be achieved by immunointervention using adenoviral vectors expressing TNF-a and IL-6 antagonists and/or by modification of Ad capsid in order to control viral tropism. 44, 45 Materials and methods
Mice
Wild-type and IL-6-deficient mice 25 were maintained on BALB/c genetic background under specified pathogenfree conditions by the Centre de Développement des Techniques Avancées pour l'expérimentation animale (CDTA, Orléans, France). C57BL/6 mice were purchased from Janvier (Le Gesnest Saint Isle, France) or Iffacredo (Lyon, France). All experiments were performed in accordance with Institutional Animal Research Committee guidelines.
Adenoviral vectors
AdCMVbgal and AdmlpAAT encoding nuclear bgal and human AAT, respectively, have been described previously. 46, 47 AdTNFR1-Ig, which was kindly provided by Dr B Beutler (Department of Immunology, The Scripps Research Institute, La Jolla, CA) encodes a TNF-a inhibitor consisting of a dimeric fusion protein between the Fc portion of mouse IgG1 and the extracellular domain of human TNFR 1 (p55). 24 AdCO1 is a recombinant Ad encoding no transgene and was used as a control. 48 Viral stocks were prepared with human embryonic kidney 293 cell monolayers and purified on two successive CsCl gradients. Desalting was performed using G50 columns (Amersham Pharmacia Biotech, Orsay, France) and viruses were frozen in PBS-7% glycerol at À801C. Titers were calculated as PFU on 911 cells. 49 Several stocks were used for each virus with a viral particle-to-PFU ratio in the range of 20-40. Endotoxin contaminations were excluded by E-Toxate kit (Sigma-Aldrich, Lyon, France).
In vivo experiments
Ad encoding a reporter gene (AdCMVbgal or AdmlpAAT) were administered to mice along with either AdTNFR1-Ig or the control AdCO1. Viruses were diluted in a volume of 200 ml of PBS and i.v. injected in the retro-orbital plexus of 3-to 4-month-old mice (body weight mean7s.d. of 21.4270.55 g and 19.870.88 g for wild-type and IL-6-deficent mice, respectively). Blood samples were collected before the virus injection and at different intervals thereafter. Mice sera were prepared and analyzed for AAT, TNFR1-Ig, cytokines and antibodies (Ab). In some experiments animals were killed at different days p.i., and livers were removed for histological analysis, monitoring of transgene expression and viral DNA content.
In some experiments, mice were pretreated 1 day before AdmlpAAT (5 Â 10 9 PFU) administration, with etanercept (Enbrel, Wyeth, France) or PBS i.p. at 10 mg/kg dose, then this regimen was continued once every 2 days for 24 days.
Hematology and measurement of serum cytokines and transaminases
Blood samples for the orbital plexus were collected in citrated tubes at indicated times. Hematological parameters were measured using an automated blood counter calibrated for blood cells (MS9, Schloessing Melet, Cergy-Pontoise, France). IL-6, TNF-a and IL-1b in mice sera were quantified using duo-set ELISAs according to the manufacturer's protocol (R&D, Abingdon, UK). Serum ALT activities were determined using Enzyline ALT/GPT 20 Kits (bioMérieux, Marcy l'étoile, France).
Measurement of human AAT and etanercept
The expression of AAT was monitored by a sandwich ELISA as previously described. 50 Briefly, 96-well microtiter plates (Maxisorp Nunc, Roskilde, Denmark) were coated with a rabbit anti-human AAT Antibody (Cappel, ICN pharmaceuticals, OH, USA), blocked with 5% milk (Regilait, Saint Martin Belle Roche, France) Tris-buffered saline-Tween; dilutions of sera or standard human AAT (Sigma-Aldrich) were then added. The linked AAT was revealed using a rabbit anti-human AAT antibody (Roche Diagnostics, Meylan, France) and an alkaline phosphatase-conjugated goat anti-rabbit antibody (Promega, Madison, WI, USA). The expression of etanercept was monitored by a sandwich ELISA using a goat anti-TNFR II (R&D) and an alkaline phosphataseconjugated goat anti-human antibody (Jackson Immunoresearch, Cambridgeshire, UK). AAT or etanercept was detected by 20-min incubation with developing solution (Alkaline Phosphatase Substrate Kit, Bio-Rad Laboratories, Hercules, CA, USA) and OD 405 nm was determined using a microplate reader.
Measurement of bgal activity
Fifty milligrams of liver sample were homogenized in lysing matrix tubes containing 1 ml of lysis buffer using the FastPrep system (Qbiogene, Illkirch, France). The lysis buffer contained 0.2% Triton X-100, 0.5 mM dithiothreitol, 100 mM potassium phosphate, and protease inhibitors (Complete, Mini, Protease inhibitor cocktail tablets, Roche Diagnostics). Homogenates were then TNF-a and IL-6 involvement in anti-Ad immune response K Benihoud et al clarified by centrifugation at 14 000 g for 15 min at 41C. After centrifugation the supernatant was measured for bgal activity using a chemiluminescent assay (Luminescent bgal detection kit II, BD Biosciences Clontech, Palo Alto, CA, USA). Protein content was determined using the Bio-Rad Protein Assay (Bio-Rad Laboratories).
Measurement of neutralizing TNFR1-Ig
TNFR1-Ig in mouse sera was quantified by its ability to neutralize TNF-a induced apoptosis of WEHI 164 clone 13 cells. Viability of the cells was assessed using a colorimetric 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. Briefly, serum samples were serially diluted in Rosewell's Park Memorial Institute (RPMI) medium containing TNF-a (Perbio Science, Brebières, France) at a final concentration of 1 ng/ml. After 1 h incubation at 371C, 50 ml sera were transferred on 96-well plates containing 2 Â 10 4 WEHI cells in RPMI medium (50 ml) supplemented with 10% fetal calf serum (FCS). Cells were incubated for 24 h at 371C, and MTT reagent (25 ml, 5 mg/ml, Sigma-Aldrich) was added 4 h before the end of incubation. After solubilization of MTT formazan crystals, optical density was determined at 570/630 nm. Neutralizing titer was calculated as the last serum dilution for which 90% of cells remain alive.
Immunostaining of liver cellular infiltrates and bgal detection
Livers samples were either (1) immediately embedded in OCT (Tissue-Tek, Miles laboratories Inc., Naperville, IN, USA), and snap-frozen in liquid nitrogen for frozen sections or (2) fixed in GlyoFix (Shandon, Pittsburgh, PA, USA), dehydrated and paraffin-embedded.
For immunostaining, frozen sections of liver (5 mm) were incubated with either a rat anti-CD4 antibody at a dilution of 1:3000 or a rat anti-CD8 antibody at a dilution of 1:1000 (PharMingen, San Diego, CA, USA). For detection of macrophages, anti-Mac1 antibody was used at a dilution of 1:600 (PharMingen). After washing, an alkaline phosphatase-conjugated rabbit anti-rat antibody (DAKO, Trappes, France) was added at a dilution of 1:50. In order to amplify the signal, an APAAP complex specific for rat (rat antibodies to calf intestinal alkaline phosphatase plus calf intestinal alkaline phosphatase) was added at a dilution of 1:25 (DAKO). Endogenous phosphatases were inhibited with levamisole (DAKO). Alkaline phosphatase activity was revealed with Fast Red substrate (DAKO) and the liver sections were counterstained with hematoxylin. As a negative control, the primary antibody was omitted.
For bgal activity, paraffin liver sections (5 mm) were incubated with rabbit polyclonal anti-bgal antibody (Cappel) at a dilution of 1:900 followed by incubation with Power Vision anti-rabbit (Microm Microtech, Francheville, France). Slides were treated with DAB chromogenic substrate system (Microm) and counterstained with Mayer's hematoxilin.
Preparation of intrahepatic mononuclear cells and flow cytometry analysis
Intrahepatic mononuclear cells were prepared as previously described. 51 Briefly, livers were cut into small pieces in 30% FCS-RPMI medium, passed through a mesh, and washed once. The cell pellet was resuspended in 10 ml of 20% FCS-RPMI medium and mononuclear cells were separated from parenchymal hepatocytes by Ficoll-Hypaque density gradient centrifugation. Erythrocytes were removed by osmotic shock.
The expression of different cell-surface antigens on intrahepatic mononuclear cells, previously incubated with a mAb to mouse Fcg receptor (clone 2.4 G2, PharMingen) to inhibit nonspecific binding, was analyzed by three-color flow cytometry using either PerCP-, FITC-or phycoerythrin-conjugated mAbs: goat antimouse IgM (F-9259, Sigma-Aldrich), anti-DX5 (antiCD49b/Pan-NK Cells, PharMingen), anti-CD11b/Mac-1 (clone M1/70, PharMingen), anti-CD3 (145-2C11, PharMingen), with irrelevant rat IgG2a or IgM mAb (Immunotech, Marseille, France) as controls. The numbers of CD3 + , CD11b + (Mac1) and DX5 + cells per entire liver was obtained by multiplying the percentage of each population with the total number of mononuclear cells per liver.
Determination of specific antibodies
The presence of Ad-specific antibodies in the sera was determined by ELISA as described previously. 22 After coating of 96-well plates (Nunc) with 100 ng of inactivated Ad, serial dilutions of the sera were added. Bound antibody was detected with peroxidase-conjugated anti-mouse IgG isotypes goat antibodies (Southern Biotechnology Associates, Birmingham, AL, USA). The peroxidase was revealed by incubation with the substrate o-Phenylenediamine dihydrochloride (SigmaAldrich) for 30 min. The reaction was stopped by addition of 3N HCl and spectrophotometric reading was performed at 490 nm.
The presence of transgene specific antibodies was determined by ELISA. Ninety six-well plates (Nunc) were coated with 100 ng of bgal or AAT (both Sigma) or human TNFR1 (R&D) and treated as above. Serial dilutions of the sera in 5% milk PBS-Tween were added, and bound antibody was detected with peroxidaseconjugated anti-mouse isotypes IgG or IgG plus IgM (Southern Biotechnology Associates). Peroxidase activity was measured as above. The presence of etanercept (Enbrel) specific antibodies was determined as reported above using 96-well plates coated with 100 ng of etanercept.
Real-time quantitative PCR
Fifty mg of liver sample was homogenized in lysing matrix tubes containing Dneasy tissue kit lysis buffer (Qiagen, Courtaboeuf, France) using the FastPrep system (Qbiogene) and total DNA was recovered according to the manufacturers instructions. To quantify the amount of viral DNA present in liver samples, duplicate samples of genomic DNA (50 ng) were subjected to PCR using the ABI Prism 7700 system and buffers provided by the manufacturer (Perkin-Elmer Applied Biosystems, Foster City, CA, USA). Primer pairs (forward: 5 0 -YCC CAT GGA YGA GCC CAC MCT-3 0 and reverse 5 0 -GAG AAS GGB GTG CGC AGG TAS-AS-3 0 ) and the fluorogenic probe (5 0 -CAC CAG CCA CAC CGC GGC GTC ATC GA-3 0 ) were designed against the adenoviral hexon gene (Y ¼ C or T, M ¼ A or C, S ¼ G or C, and B ¼ C or G or T). 52 The 5 0 -and 3 0 -end of the probe are linked with a reporter dye (6-carboxyfluorescein) and a quencher dye (6-carboxy-N, TNF-a and IL-6 involvement in anti-Ad immune response K Benihoud et al N, N 0 , N 0 -tetramethylrhodamine), respectively. The specificity of Ad5 PCR products was confirmed using 1 mg of human and murine genomic DNA (Roche Molecular Biochemicals, Meylan, France). Samples were amplified for 50 PCR cycles with continuous monitoring of fluorescence. To quantify the amount of genomic DNA, a second real-time PCR was performed using two primers (forward: 5 0 -CCT GCC CTC CTG CTG ACT ATT-3 0 and reverse: 5 0 -GCC AAC CAT GAT GTG CTG AA-3 0 ) and the fluorogenic probe (5 0 -TTC ATC TTT GCC AAC GTC AGT GAG GCA-3 0 ) located in the mouse b2-microglobulin gene. Results were expressed as the number of PFU equivalents 52 per microgram of genomic DNA.
Statistics
Data were compared using a one-way ANOVA with Fisher's least significant difference test.
